Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to -$521958.0.

  • Evoke Pharma's Cash from Operations rose 3624.51% to -$521958.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 3756.53%. This contributed to the annual value of -$5.5 million for FY2024, which is 950.39% down from last year.
  • Per Evoke Pharma's latest filing, its Cash from Operations stood at -$521958.0 for Q3 2025, which was up 3624.51% from -$565018.0 recorded in Q2 2025.
  • Over the past 5 years, Evoke Pharma's Cash from Operations peaked at -$521958.0 during Q3 2025, and registered a low of -$5.9 million during Q3 2021.
  • Moreover, its 5-year median value for Cash from Operations was -$1.2 million (2024), whereas its average is -$1.7 million.
  • Per our database at Business Quant, Evoke Pharma's Cash from Operations tumbled by 22543.76% in 2021 and then skyrocketed by 8131.54% in 2022.
  • Quarter analysis of 5 years shows Evoke Pharma's Cash from Operations stood at -$2.0 million in 2021, then dropped by 25.49% to -$2.5 million in 2022, then skyrocketed by 55.87% to -$1.1 million in 2023, then dropped by 12.11% to -$1.2 million in 2024, then skyrocketed by 57.91% to -$521958.0 in 2025.
  • Its last three reported values are -$521958.0 in Q3 2025, -$565018.0 for Q2 2025, and -$997509.0 during Q1 2025.